gbola amusa md cfa head hc research
sale trade et
viral news genet medicin zolgensma bn break-up scenario
highlight week januari februari novarti announc result includ mm
sale mm mm mm gene therapi gt zolgensma
spinal muscular atrophi sma note zolgensma launch outpac spinraza
unrat forecast buy chardan top pick report mm zolgensma
royalti revenu novarti estim mm per year royalti went
npv royalti approxim bn anoth factor support view
rnai-therapeut givosiran acut hepat porphyria ahp posit opinion base result phase
envis trial recal novemb alnylam announc fda approv givosiran ahp see
novemb research unrat unrat announc phase ii trial
antisens oligonucleotid aso patient hypertriglyceridemia type
diabet non-alcohol fatti liver diseas met primari endpoint result studi show signific
p-valu provid reduct compar placebo fast triglycerid dose-depend reduct addit
marker cardiovascular metabol diseas includ apoc-iii vldl-c non-hdl cholesterol total
cholesterol januari akcea ioni announc posit result anoth aso akcea-apociii-lrx
cardiovascular diseas autolu therapeut announc updat data phase i/ii alexand trial
dual-target cell therapi adult relapsed/refractori diffus larg cell lymphoma
dlbcl result announc patient dose cell plu pembrolizumab show patient
achiev respons complet partial achiev complet respons addit across dose level
complet respond maintain on-going complet respons median follow-up month
look forward februari februari februari februari european associ hemophilia
alli disord eahad annual congress held hagu program includ catalyst bioscienc
buy uniqur buy chardan top pick februari present addit
optic phase trial data angiogenesi exud degener meet miami
follow compani report financi result takeda pharmaceut unrat februari et
squibb unrat et sanofi unrat februari et
weekli price move vivo genet medicin aav srna mrna vivo gene edit
mrna mm vivo gene edit mm contributor buy mm
upcom chardan genet medicin event contact chardan rsvp
march chardan present sponsor gene therapi genom edit summit host
dr jim wilson dr fulvio mavilio dr andi scharenberg miami
april chardan sponsor arm cell gene meet mediterranean barcelona
pleas refer import disclosur inform regul analyst certif found page report
gene express fda provid visibl sames odd
januari fda announc releas final guidanc document draft guidanc provid better
regulatori clariti develop genet medicin final guidanc document build upon draft releas
fda juli see juli research among document draft guidanc interpret same
gene therapi product orphan drug regul determin same human gene therapi
purpos relat orphan drug design exclus
recal treatment includ gene therapi may qualifi orphan design intend rare diseas
suffici scientif rational establish medic plausibl basi efficaci rare diseas benefit
orphan drug design odd includ financi incent tax credit qualifi clinic test exempt
prescript drug user fee market applic year orphan-drug exclus
sponsor must provid plausibl hypothesi support clinic superior appli drug gene therapi
similar indic approv drug gene therapi asset definit same
clearli establish purpos odd toward clearer definit fda present concept
princip molecular structur featur use establish same present scenario guid develop
exampl gene therapi product express differ transgen use differ vector consid
differ product purpos odd likewis gene therapi product use vector deriv differ viral
class exampl herpesviru vs adenoviru two product consid differ howev fda intend
determin same basi vector class case case basi
releas draft guidanc final guidanc document us affirm fda support gene
therapi space believ draft guidanc same logic us expect characterist tend
chang qualiti gene therapi transgen capsid etc fda use determin
product
qure buy chardan top pick januari amusa
uniqur januari research becam chardan top pick also chardan genet
medicin top pick thesi updat highlight follow reason despit qure run
mm market cap bn qure still offer except risk-reward dynam
 etranadez hemophilia alon justifi current valuat uniqur
 uniqur could achiev unrat sarepta therapeutics-lik valuat alon compani succe
phase i/ii huntington diseas trial
 uniqur still valuat show enough upsid acquir given compani first- best-
manufactur consider manufactur capac capabl
buy zolgensmalook good approv rate launch januari amusa
chardan top pick earn royalti zolgensma sale report januari
unrat novarti mm mm mm mm total
zolgensma sale thu suggest mm royalti revenu mm report
see reason zolgensma may see sale momentum pass mm global sale
us potenti zolgensma royalti could worth bn npv
buy chardan top pick bn break-up stori januari amusa
januari research becam chardan top pick also chardan genet
medicin top pick summar reason share offer except risk-reward dynam
beyond focus particular billion valuat impli break-up see
 pipelin program intern extern partner de-risk
 consensu like model product candid high potenti estim upgrad
 newli benefit approv zolgensma
 per recent updat anti-vegf franchis could move pivot phase statu recal buy-rat kodiak
scienc stock price move transit emerg best-in-class gene therapi gt statu
data new in-offic suprachoroid deliveri use microinjector
page
break-up compani intern program external/royalti program impli
valuat billion would also increas likelihood takeout highlight reason
 billion valuat navtech newco royalti stream valuat spun
 billion valuat monogen rare diseas portfolio mp ii mp diseas hofh
 billion valuat anti-vegf wet dr franchis
 billion valuat vector ab portfolio
 billion valu cash
buy chardan top pick derisk platform januari amusa
meiragtx januari research becam chardan top pick also chardan genet
medicin top pick rate meira buy forward-look approach manag taken develop
one broadest pipelin aav-bas gene therapi gt includ one lower-risk inherit retin
diseas ird opportun earli win higher-risk large-market opportun
 meira collabor equiti stake johnson johnson unrat
 meira on-going clinic program provid potenti upcom valu inflect point strong
summar reason share offer except risk-reward dynam
compani broadli derisk valid cash-infus meira may signal long-term interest
preclin pipelin potenti transform therapi
 given strong balanc sheet meira flexibl focu larg gene therapi market opportun
 meiragtx lever gene regul via switch technolog
 phase ii aav-gad could solut parkinson patient current standard care
buy chardan top pick idea shot mc januari amusa
januari research becam chardan top pick also chardan genet
medicin top pick reiter view krystal rank among uniqu complet gt
compani given krystal clinical-stag hsv-base gt product expand preclin pipelin intern
commerci gt manufactur facil also ad krystal list like gt acquisit target
addit logic krystal uniqu offer reason beyond
 krystal gener potenti breakthrough clinic data rmat/prim phase i/ii trial hsv-base
gene therapi bvec dystroph epidermolysi bullosa deb
 b-vec data posit implic krystal tough-to-repl star-d gt platform
 krystal may clinic program could ultim lead billion valuat
gene edit theme expect potenti transform januari livshit
highlight key theme present expect potenti transform year
ex vivo vivo gene edit ge space ex vivo proof-of-concept establish
hemoglobinopathi crispr buy unrat see potenti new
oncolog data crispr tx gene edit compani drive perform
vivo ge segment continu lag ex vivo note multipl clinic catalyst potenti
transform year buy intellia buy logicbio buy
broadli see potenti inflect gene edit space segment fundament includ
better understand safeti edit profil human better visibl clinic paramet allogen
cell-bas immunotherapi increas regulator/clinician/pati comfort idea human gene edit
genet medicin news januari februari
neutral announc open new hq redwood citi california januari
centuri therapeut privat announc appoint dr greg russotti januari
unrat announc unrat result aso januari
akcea ioni pharmaceut announc posit top-line result phase ii studi
subcutaneously-inject antisens oligonucleotid aso patient
hypertriglyceridemia type diabet non-alcohol fatti liver diseas nafld studi met primari endpoint
addit secondari endpoint demonstr favor safeti profil
page
statist signific reduct fast triglycerid compar placebo report addit dose
depend reduct apoc-iii vldl-c non-hdl cholesterol total cholesterol report
result trial share unrat set strategi subsequ develop
compani plan present result futur medic confer
mogrifi privat announc mm fund advanc cell therapi research platform januari
passag privat announc appoint dr bruce goldsmith ceo januari
unrat announc result provid busi updat januari
nv unrat announc result provid updat busi oper januari
umrx unrat announc updat pi trial t-cell-bas solid tumor januari
ortx unrat announc orphan drug design autolog gt x-cgd januari
decibel privat announc appoint dr laurenc reid act ceo januari
decibel privat announc refocus regen medicin inner ear januari
unrat announc collab celular privat nk cell-tx coronavirus januari
cgt catapult privat announc appoint matthew durdi chief execut offic januari
autl unrat announc pi/ii trial data cell therapi relaps refractori dlbcl januari
autolu therapeut announc european cell meet updat data phase i/ii alexand
trial dual-target cell therapi adult relapsed/refractori diffus larg cell lymphoma
partial achiev complet respons cr result build data report decemb
american societi hematolog annual meet across dose level patient
achiev complet respons remain cr median month follow-up
importantli safeti instanc cytokin releas syndrom grade higher primari
treatment though patient experi grade upon re-treat patient experienc grade
neurotox though patient treat pembrolizumab experienc neurotox grade
unrat collabor beij advaccin biotechnolog privat cov januari
inovio pharmaceut announc collabor beij advaccin biotechnolog develop dna-bas
vaccin newli emerg coronaviru china
recal septemb inovio publish safeti immunogen dna vaccin mer
coronaviru phase studi found seroconvers subject subject
vaccin respect caution read-across differ virus studi provid
evid dna-bas vaccin elicit immun coronavirus
addit compani work toward treatment vaccin novel coronaviru infect includ moderna
buy gilead unrat curevac privat sorrento unrat other note timelin
current coronaviru outbreak current project novel vaccin may therefor completed/
produc time situat provid opportun compani demonstr design manufactur
agil dna- rna-bas vaccin platform
unrat announc result pi trial microrna inhibitor cobomarsen atll januari
unrat announc result provid updat corpor progress januari
buy announc appoint dr melani ivarsson chief develop offic januari
unrat publish antigen respons outcom t-cell-bas therapi januari
rhhbi unrat announc result provid busi updat januari
ortx unrat publish genethon privat pi/ii trial ex vivo lentivir gt x-cgd januari
unrat announc result updat corpor progress januari
prqr unrat announc rare pediatr diseas design rna-bas rp januari
unrat announc result provid updat busi oper januari
unrat announc patient dose pib trial allogen cell tx pku januari
page
unrat announc open cell gene therapi manufactur facil nj januari
mammoth bioscienc privat announc mm seri crispr-bas product januari
alsen fp unrat announc preclin data aav gt model hear loss januari
unrat announc result updat corpor progress januari
buy announc posit opinion chmp rna-bas givosiran ahp januari
announc posit opinion chmp rnai-therapeut givosiran acut hepat
porphyria basi result phase envis trial
curevac privat announc continu collab cepi mrna-bas vaccin januari
phio unrat file form propos mm max offer equiti secur januari
compani mention report
page
corpor report factset chardan note mention stock unrat unless state select public gm compani includ adhera therapeut
benitec biopharma buy lysogen oncosec medic oxford biomedica neutral vbl buy
figur select price movement week end jan vivo gm perform aav srna mrna ivg
page
week-over-week perform vivo genet medicin aav srna mrna vivo gene edit basketstickerratingccm ptupsideclosechang changemc mm genet medicin cap genet medicin vivo cap genet medicin ex vivo cap gene therapytickerratingccm ptupsideclosechang changemc mm prevail genet therapytickerratingccm ptupsideclosechang changemc mm dicerna gene editingtickerratingccm ptupsideclosechang changemc mm logicbio pharmaceut
vivo genet medicin monthli market cap progress select compani
corpor report factset chardan note avx nite static market cap contribut post acquisit ise exclud
figur aav-bas gene therapyend-monthli market cap select compani januari present
figur srna mrna therapyend-monthli market cap select compani januari present
figur vivo gene editingend-monthli market cap select compani januari present
page
cap million aav gt sector market cap time includ acquir cap million srna mrna gt sector market cap cap million vivo gene edit sector market cap pharmaceut
aav-bas gene therapi comp meiragtx uniqur chardan top pick
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name ise model current market cap
refer partner product avexi novarti compani wet hofh mp mp ii phase i/ii trial
figur select public aav-bas gene therapi companiesw prefer buy buy qure buy greater potenti drive upsid aav-bas gt space
page
targettargetccmphas ofpriceccmccmdiluteddil mcpercentccm ptshare mmof sector mmof sectorhighshareabeona genet privat aav-bas genetherapi molecular ask estev horama stride tamid taysha gene therapi pharmaceut
srna mrna therapi comp alnylam top pick
corpor report factset chardan note mention stock unrat unless state target market cap unrat name bntx model current market cap
figur select public srna mrna therapi companiesw prefer buy buy greater potenti drive upsid entir srna mrna space
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitalnylam privat srna mrna therapi companiesadvirna silense sirnaom somagen sylenti curevac ethri etherna immunotherapi genev scienc strand therapeuticsnot adhera therapeut benitec pharma regulu technolog pharmaceut
vivo gene edit comp see greater upsid potenti intellia toolgen
corpor report factset chardan note mention stock unrat unless otherwis state target market cap unrat name model current market cap
figur vivo gene editingw broadli expect out-performance crispr sector higher potenti perform buy toolgen buy
page
targettargetccmphas ofpriceccmccmdil mcpercentccm pt mmof sector mmof sectorhighshareof profitcrispr privat vivogen edit companiesbeam egenesi emendo therapeut excis recombinet spotlight trucod gene repair verv technolog pharmaceut
genet medicin therapeut approv posit opinion fda and/or ema
date
date
corpor report fda ema chardan note market author glybera expir due uniqur decis appli renew exclud antisens oligonucleotid figur
figur believ recent increas rate approv posit opinion genet medicin sign sector rapidli emerg
page
genet medicin therapeut receiv fda breakthrough therapi ema prime design
date fda btd
date ema prime
hattr amyloidosi polyneuropathi
corpor report fda ema biopharm insight chardan note ema start grant prime design may fda start grant breakthrough therapi design juli
figur believ disproportion amount btd prime design award genet medicin anoth sign sector rapidli emerg
page
date fda rmat
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur regen medicin advanc therapi design allow compani interact fda earlier clinic test process frequent
prioriti review voucher prv valu prv sold compani compani
date prv sale
swedish orphan biovitrum astrazeneca
ultragenyx undisclos
spark
ultragenyx novarti
biomarin undisclos
sarepta gilead
unit abbvi
sanofi
knight gilead
biomarin sanofi/regeneron pharmaceut
figur prioriti review voucher prv sold million million
price prv
page
date fda rpdd
ultragenyx genetx
corpor report fda biopharm insight chardan note list rpdd may incomplet sinc exampl compani disclos regulatori design
figur sinc pediatr diseas design potenti lead prioriti review voucher drug approv hidden sourc valu exist compani
page
date fda ftd
crispr vertex
crispr vertex
parkinson diseas mutat
rp due mutat exon gene
moder sever local scleroderma
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
date fda ftd
corpor report fda biopharm insight chardan note list may incomplet sinc exampl compani disclos regulatori design
figur track design facilit develop process expedit review drug seriou condit unmet medic need
page
genet medicin select therapeut receiv btd rmat prime rpdd and/or ftd us eu
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genetx ultragenyx
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
parkinson diseas mutat
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design
figur us/eu regulatori designationsa number genet medicin product receiv fda/ema design speed regulatori process and/or provid market exclus
page
genet medicin regulatori design btd rmat prime ftd rpdd grant time
corpor report chardan note list may incomplet sinc exampl compani disclos regulatori design ema start grant prime design may
fda start grant breakthrough therapi design btd juli pediatr diseas design rpdd rmat design genet medicin began novemb
figur regulatori design btd rmat prime ftd rpdd grant genet medicin consider increas grant
page
designationsyear design grantedgenet medicin regulatori design ytd btdrmatprimeftdrpdd biotechnolog pharmaceut
